头孢他啶治疗严重细菌感染
Ceftazidime therapy of serious bacterial infections.
作者信息
Eron L J, Goldenberg R I, Park C H, Poretz D M
出版信息
Antimicrob Agents Chemother. 1983 Feb;23(2):236-41. doi: 10.1128/AAC.23.2.236.
Abstract
Ceftazidime, a new broad-spectrum cephalosporin, was administered to 30 patients with serious bacterial infections in a randomized dosing trial with daily doses of 1.5 or 3 g. Both regimens were equally efficacious, with satisfactory clinical responses in 28 instances (93%) and microbiological eradication of 79% of initial bacterial isolates. The development of resistance to ceftazidime during therapy was observed in three cases (Enterobacter agglomerans, Enterobacter cloacae, and Pseudomonas aeruginosa) and superinfection by a resistant Enterobacter agglomerans strain occurred in one case. Adverse reactions of clinical significance included one case each of leukopenia, azotemia, diarrhea (Clostridium difficile toxin positive), and rash.
摘要
头孢他啶是一种新型广谱头孢菌素，在一项随机给药试验中，对30例严重细菌感染患者每日给予1.5克或3克剂量。两种给药方案疗效相当，28例（93%）临床反应良好，79%的初始分离细菌实现微生物学清除。治疗期间观察到3例（聚团肠杆菌、阴沟肠杆菌和铜绿假单胞菌）出现对头孢他啶的耐药性，1例发生耐聚团肠杆菌菌株的二重感染。具有临床意义的不良反应包括白细胞减少、氮质血症、腹泻（艰难梭菌毒素阳性）和皮疹各1例。
相似文献
1
Ceftazidime therapy of serious bacterial infections.头孢他啶治疗严重细菌感染
Antimicrob Agents Chemother. 1983 Feb;23(2):236-41. doi: 10.1128/AAC.23.2.236.
2
Ceftazidime in patients with Pseudomonas infections.
J Antimicrob Chemother. 1983 Jul;12 Suppl A:161-9. doi: 10.1093/jac/12.suppl_a.161.
3
Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms.头孢他啶在严重感染治疗中的应用，包括由多重耐药菌引起的感染。
Antimicrob Agents Chemother. 1983 Aug;24(2):176-80. doi: 10.1128/AAC.24.2.176.
4
Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.头孢比普：一种广谱抗耐甲氧西林金黄色葡萄球菌头孢菌素的综述。
Am J Clin Dermatol. 2008;9(4):245-54. doi: 10.2165/00128071-200809040-00004.
5
International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections.头孢吡肟与头孢他啶治疗严重细菌感染的国际比较研究。
J Antimicrob Chemother. 1993 Nov;32 Suppl B:175-86. doi: 10.1093/jac/32.suppl_b.175.
6
Ceftazidime in severe infections: a Swiss multicentre study.头孢他啶用于严重感染：一项瑞士多中心研究。
J Antimicrob Chemother. 1983 Jul;12 Suppl A:139-46. doi: 10.1093/jac/12.suppl_a.139.
7
Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model.在体外感染模型中，头孢吡肟、头孢他啶、头孢噻肟和头孢曲松对金黄色葡萄球菌以及产β-内酰胺酶的产气肠杆菌和肺炎克雷伯菌的杀菌活性。
Antimicrob Agents Chemother. 1995 Aug;39(8):1764-71. doi: 10.1128/AAC.39.8.1764.
8
Use of ceftazidime in the treatment of severe localized and systemic infections.头孢他啶在治疗严重局部和全身感染中的应用。
Int J Clin Pharmacol Ther Toxicol. 1984 Mar;22(3):167-9.
9
Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections.一种新型胃肠外抗生素在严重细菌感染治疗中的临床应用。
Am J Med. 1996 Jun 24;100(6A):52S-59S. doi: 10.1016/s0002-9343(96)00108-8.
10
Impact of voluntary vs enforced compliance of third-generation cephalosporin use in a teaching hospital.
Arch Intern Med. 1992 Mar;152(3):554-7.
引用本文的文献
1
Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome.头孢吡肟与头孢他啶作为严重细菌感染和脓毒症综合征初始治疗的比较。
Antimicrob Agents Chemother. 1994 Mar;38(3):415-21. doi: 10.1128/AAC.38.3.415.
2
Imipenem versus moxalactam in the treatment of serious infections.亚胺培南与拉氧头孢治疗严重感染的比较
Antimicrob Agents Chemother. 1983 Dec;24(6):841-6. doi: 10.1128/AAC.24.6.841.
3
Ceftazidime as initial therapy for suspected bacterial infections in hospitalized pediatric patients.头孢他啶作为住院儿科患者疑似细菌感染的初始治疗药物。
Antimicrob Agents Chemother. 1984 Sep;26(3):318-21. doi: 10.1128/AAC.26.3.318.
4
Respiratory superinfections after the use of third-generation cephem antibiotics.使用第三代头孢菌素类抗生素后的呼吸道二重感染。
Infection. 1985;13 Suppl 1:S89-95. doi: 10.1007/BF01644226.
5
Moxalactam in nosocomial infections with Serratia marcescens.莫西拉坦治疗粘质沙雷氏菌医院感染
Intensive Care Med. 1985;11(4):179-83. doi: 10.1007/BF00272399.
6
Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia.头孢他啶与头孢孟多治疗社区获得性肺炎的比较。
Antimicrob Agents Chemother. 1985 Jul;28(1):146-8. doi: 10.1128/AAC.28.1.146.
7
Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.头孢他啶。对其抗菌活性、药代动力学特性及治疗用途的综述。
Drugs. 1985 Feb;29(2):105-61. doi: 10.2165/00003495-198529020-00002.
8
Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli.头孢他啶或替卡西林与妥布霉素治疗革兰氏阴性杆菌所致骨髓炎的随机评估。
Antimicrob Agents Chemother. 1986 Jan;29(1):112-5. doi: 10.1128/AAC.29.1.112.
9
Urinary alanine-aminopeptidase (AAP) excretion in patients with urinary tract infection treated with ceftazidime (CAZ) or cefotaxime (CTX) plus tobramycin (TOB).接受头孢他啶（CAZ）或头孢噻肟（CTX）加妥布霉素（TOB）治疗的尿路感染患者的尿丙氨酸氨基肽酶（AAP）排泄情况。
Int Urol Nephrol. 1988;20(5):461-70. doi: 10.1007/BF02550604.
本文引用的文献
1
GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.GR 20263，一种具有抗假单胞菌活性的新型广谱头孢菌素。
Antimicrob Agents Chemother. 1980 May;17(5):876-83. doi: 10.1128/AAC.17.5.876.
2
Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa.头孢他啶的抗菌活性及β-内酰胺酶稳定性，一种对铜绿假单胞菌可能具有活性的氨噻唑基头孢菌素。
Antimicrob Agents Chemother. 1982 Jan;21(1):11-8. doi: 10.1128/AAC.21.1.11.
3
Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy.羟羧氧酰胺菌素治疗对头孢噻吩耐药菌引起的感染：血清抑制活性对治疗期间临床反应及抗生素耐药性获得的影响
Antimicrob Agents Chemother. 1981 Sep;20(3):351-5. doi: 10.1128/AAC.20.3.351.
4
Ceftazidime--a new extended-spectrum cephalosporin.头孢他啶——一种新型广谱头孢菌素。
Lancet. 1982 May 22;1(8282):1152-6. doi: 10.1016/s0140-6736(82)92228-0.
5
Simplified, accurate method for antibiotic assay of clinical specimens.临床标本抗生素检测的简化、准确方法。
Appl Microbiol. 1966 Mar;14(2):170-7. doi: 10.1128/am.14.2.170-177.1966.
Zotero 插件